💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Rapacuronium

CHEMBL1201352 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
597.9 g/mol
LogP
7.6
Phase
4

Rapacuronium is a rapid-onset, short-acting non-depolarizing aminosteroid neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic receptor at the neuromuscular junction, producing rapid neuromuscular blockade suitable for tracheal intubation. It was withdrawn from clinical use due to a significantly higher than expected incidence of severe bronchospasm, particularly in patients with asthma.

Молекулярная масса

597,9000 g/mol

LogP

7,60

TPSA

55,80 Ų

Правило пяти Липинского

Не соответствует

Механизм действия

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1

                

                

                
                

                    
InChI

                    
InChI=1S/C37H61N2O4/c1-6-20-39(21-12-9-13-22-39)32-24-30-28-15-14-27-23-33(42-26(3)40)31(38-18-10-8-11-19-38)25-37(27,5)29(28)16-17-36(30,4)35(32)43-34(41)7-2/h6,27-33,35H,1,7-25H2,2-5H3/q+1/t27-,28+,29-,30-,31-,32-,33-,35-,36-,37-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C37H61N2O4+

                    

                    
                    

                        
HBD / HBA

                        
- / 5

                    

                    
                    

                        
Вращаемые Связи

                        
9

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
43

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
Rapacuronium is a rapid-onset, short-acting non-depolarizing aminosteroid neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic receptor at the neuromuscular junction, producing rapid neuromuscular blockade suitable for tracheal intubation. It was withdrawn from clinical use due to a significantly higher than expected incidence of severe bronchospasm, particularly in patients with asthma.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Rapacuronium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201352.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5311399.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.